PMV PHARMACEUTICALS INC's ticker is PMVP and the CUSIP is 69353Y103. A total of 106 filers reported holding PMV PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 0.78 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,444,859 | -35.2% | 235,319 | -33.9% | 0.00% | – |
| Q2 2023 | $2,228,221 | -25.9% | 355,946 | -43.5% | 0.00% | – |
| Q1 2023 | $3,006,335 | -69.7% | 630,259 | -44.7% | 0.00% | -100.0% |
| Q4 2022 | $9,911,579 | -36.6% | 1,139,262 | -13.3% | 0.00% | -50.0% |
| Q3 2022 | $15,635,000 | -64.4% | 1,313,903 | -57.4% | 0.00% | -66.7% |
| Q2 2022 | $43,975,000 | -51.9% | 3,085,963 | -29.7% | 0.01% | -50.0% |
| Q1 2022 | $91,381,000 | +1113.6% | 4,389,070 | +1246.5% | 0.01% | +1100.0% |
| Q4 2021 | $7,530,000 | +567.6% | 325,967 | +760.3% | 0.00% | – |
| Q3 2021 | $1,128,000 | -51.7% | 37,889 | -44.5% | 0.00% | – |
| Q2 2021 | $2,335,000 | +592.9% | 68,328 | +568.4% | 0.00% | – |
| Q1 2021 | $337,000 | -82.8% | 10,223 | -67.8% | 0.00% | – |
| Q4 2020 | $1,956,000 | +698.4% | 31,796 | +360.8% | 0.00% | – |
| Q3 2020 | $245,000 | – | 6,900 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Euclidean Capital LLC | 4,179,416 | $257,076,000 | 54.42% |
| INTERWEST VENTURE MANAGEMENT CO | 6,469,911 | $397,964,000 | 49.71% |
| Octagon Capital Advisors LP | 250,000 | $15,378,000 | 5.33% |
| Boxer Capital, LLC | 2,268,236 | $139,519,000 | 4.48% |
| COMMODORE CAPITAL LP | 125,000 | $7,689,000 | 4.18% |
| Orbimed Advisors | 7,330,423 | $450,894,000 | 3.95% |
| Asymmetry Capital Management, L.P. | 96,595 | $5,942,000 | 2.71% |
| Avoro Capital Advisors LLC | 2,350,267 | $130,536,000 | 2.25% |
| RA Capital Management | 1,710,265 | $105,198,000 | 1.47% |
| HighVista Strategies LLC | 22,654 | $1,393,000 | 0.89% |